Shree Ganesh Remedies DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024


0.74×	0.74×	0.74×
0.98×	1.06×	1.07×
22.5%	27.3%	28.4%
0.55×	0.60×	0.74×
1.27×	1.32×	1.40×
11.4%	16.9%	23.1%
11.5%	17.3%	23.0%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SGRL₹639.75

Shree Ganesh Remedies Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SHUKRAPHAR SUNLOCMcap ₹822 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.74	0.74
Interest Burden (Pretax/EBIT) ×	1.07	1.06	0.98
EBIT Margin %	28.36	27.30	22.46
Asset Turnover ×	0.74	0.60	0.55
Financial Leverage (Assets/Equity) ×	1.40	1.32	1.27
ROE (5-step product, year-end total equity) %	23.14	16.87	11.40
ROE (owners' profit / average owners' equity) %	23.03	17.28	11.53

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.